Hematologic profile and complications in patients with PV according to JAK2 genotype
. | JAK2 genotype . | . | . | P . | . | . | ||||
|---|---|---|---|---|---|---|---|---|---|---|
. | Tnull; wild type . | Timinor; T allele up to 50% . | Tmajor; T allele more than 50% . | Global . | Tnull vs Tminor . | Tminor vs Tmajor . | ||||
| No. of patients | 13 | 35 | 12 | — | — | — | ||||
| Age at diagnosis, y (range) | 42 (25-71) | 56 (39-86) | 63 (27-86) | .01 | <.001 | .66 | ||||
| Age at inclusion, y (range) | 48 (27-78) | 67 (41-90) | 70 (28-90) | .03 | .013 | .73 | ||||
| Duration of the disease, mo (range) | 79 (1-112) | 88 (0-366) | 69 (6-227) | .83 | .60 | .96 | ||||
| Hematologic profile | ||||||||||
| White blood cell count, × 109/L (range) | 8 (6-13) | 13 (5-26) | 12 (6-24) | .004 | .001 | .83 | ||||
| Platelet count, × 109/L (range) | 225 (142-840) | 537 (184-1208) | 549 (240-966) | .003 | .001 | .89 | ||||
| Splenomegaly, yes/no | 3/10 | 14/19 | 6/6 | .34 | .32 | .65 | ||||
| EEC, yes/no | 6/7 | 28/7 | 10/2 | .04 | .02 | 1 | ||||
| Complications | ||||||||||
| Follow-up, y (range) | 10 (0.2-19) | 8 (1-30) | 7 (1-23) | .70 | .39 | .97 | ||||
| Treatment, yes/no | 6/7 | 34/1 | 11/1 | <.001 | <.001 | .45 | ||||
| Thrombotic events, yes/no | 1/12 | 6/29 | 2/10 | .71 | .66 | 1 | ||||
| Probabilities of hematologic complications, % | ||||||||||
| 5 y after diagnosis | 0 | 4 ± 2 | 29 ± 12 | — | — | — | ||||
| 10 y after diagnosis | 0 | 10 ± 7 | 29 ± 12 | .12 | .79 | .14 | ||||
| Survival rates, % | ||||||||||
| 10 y after diagnosis | 100 | 87 ± 9 | 76 ± 15 | — | — | — | ||||
| 15 y after diagnosis | 83 ± 15 | 87 ± 9 | 38 ± 20 | .15 | .82 | .08 | ||||
. | JAK2 genotype . | . | . | P . | . | . | ||||
|---|---|---|---|---|---|---|---|---|---|---|
. | Tnull; wild type . | Timinor; T allele up to 50% . | Tmajor; T allele more than 50% . | Global . | Tnull vs Tminor . | Tminor vs Tmajor . | ||||
| No. of patients | 13 | 35 | 12 | — | — | — | ||||
| Age at diagnosis, y (range) | 42 (25-71) | 56 (39-86) | 63 (27-86) | .01 | <.001 | .66 | ||||
| Age at inclusion, y (range) | 48 (27-78) | 67 (41-90) | 70 (28-90) | .03 | .013 | .73 | ||||
| Duration of the disease, mo (range) | 79 (1-112) | 88 (0-366) | 69 (6-227) | .83 | .60 | .96 | ||||
| Hematologic profile | ||||||||||
| White blood cell count, × 109/L (range) | 8 (6-13) | 13 (5-26) | 12 (6-24) | .004 | .001 | .83 | ||||
| Platelet count, × 109/L (range) | 225 (142-840) | 537 (184-1208) | 549 (240-966) | .003 | .001 | .89 | ||||
| Splenomegaly, yes/no | 3/10 | 14/19 | 6/6 | .34 | .32 | .65 | ||||
| EEC, yes/no | 6/7 | 28/7 | 10/2 | .04 | .02 | 1 | ||||
| Complications | ||||||||||
| Follow-up, y (range) | 10 (0.2-19) | 8 (1-30) | 7 (1-23) | .70 | .39 | .97 | ||||
| Treatment, yes/no | 6/7 | 34/1 | 11/1 | <.001 | <.001 | .45 | ||||
| Thrombotic events, yes/no | 1/12 | 6/29 | 2/10 | .71 | .66 | 1 | ||||
| Probabilities of hematologic complications, % | ||||||||||
| 5 y after diagnosis | 0 | 4 ± 2 | 29 ± 12 | — | — | — | ||||
| 10 y after diagnosis | 0 | 10 ± 7 | 29 ± 12 | .12 | .79 | .14 | ||||
| Survival rates, % | ||||||||||
| 10 y after diagnosis | 100 | 87 ± 9 | 76 ± 15 | — | — | — | ||||
| 15 y after diagnosis | 83 ± 15 | 87 ± 9 | 38 ± 20 | .15 | .82 | .08 | ||||
Plus/minus values indicate standard deviation.
— indicates not calculated.